Gross Margin

Despite better margins, CCSC's net loss ballooned 240%. A deep dive into its costly strategy to pivot towards ESG and a resilient global supply chain.

AI learning platform Docebo launches a major share repurchase, betting on its own undervaluation while posting strong growth and navigating a client shift.

As Brilliant Earth preps its Q2 results, the firm faces a critical test. Is its celebrated ethical model a true market moat or a luxury in a downturn?

As activist investor Goldenwise demands board seats, Phunware fires back, defending its AI-powered strategy and raising questions about the investor's credibility.

As demand for battle-proven drones soars, AIRO’s major RQ-35 delivery proves that controlling the entire supply chain is the key to winning in defense.

The firm reported a Q4 loss but a record $111M backlog fuels its ambitious plan for $150M revenue and a pivot to high-growth quantum and defense markets.

With record earnings and a massive expansion plan, Dutch giant ASML is the critical linchpin in the AI revolution. Why its every move shapes our digital future.

As Paysign prepares its Q2 2026 results, the numbers are secondary. The real story is its pivotal role in reshaping patient affordability in a complex era.

A small-cap delivery firm posts a staggering loss despite revenue growth. It's not a sign of failure, but a high-stakes bet on AI. Here's the why behind the buy-in.

With revenue down 22% and losses widening, JCTC's Q3 looks grim. But a stronger balance sheet and insider buying hint at a deliberate, high-stakes pivot.

As Ribbon Communications prepares its Q2 results, investors watch for proof that its AI and optical growth can overcome market headwinds and project delays.

A 44% profit jump on flat volume? NextNRG's AI-driven efficiency shows a future where energy value is created by algorithms, not just output.

As solar tracker giant Array Technologies preps its Q2 results, we look beyond the numbers at the market forces and strategic shifts defining the industry.

After a disastrous quarter, less-lethal tech firm Byrna Technologies is cutting operations, acquiring a rival, and betting its future on a major marketing blitz.

Ultragenyx bets 62% of its budget on R&D while unprofitable. Its new Impact Report reveals a strategy where patient access and ESG are the real assets.

The RF tech firm's dual move to repurchase shares and terminate its ATM offering signals robust financial health and a strategic pivot to enhance shareholder value.

A Nasdaq firm boasts impressive crypto yields and a vision to audit AI. But beneath the stable facade, it's built on a token that has lost 98% of its value.

As Merit Medical preps its Q2 report, investors are watching more than numbers. Key acquisitions and product launches signal a deeper strategic shift.

China Yuchai's robust dividend reflects a stellar 2025, but the real story is its deep investment in electric, hybrid, and fuel cell tech for a new era.